Concepedia

Tejashri Purohit-Sheth

TP

Statistics

Publications

5

Citations

147

H-Index

5

Active since

2013

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Biologics Evaluation and Research

Tejashri Purohit-Sheth is an author at United States Food and Drug Administration specializing in oncology, cancer therapeutics, and cancer research.

Top concepts

Publications per year

2013–2024

5

Publications

5

Central site monitoring: Results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection

Anne S. Lindblad, Zorayr Manukyan, Tejashri Purohit-Sheth et al. · Clinical Trials · 2013 · 44 citations

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Najat Bouchkouj, Xue Lin, Xiaofei Wang et al. · The Oncologist · 2022 · 41 citations · Full text

, , +21

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

Najat Bouchkouj, Megan Zimmerman, Yvette L. Kasamon et al. · The Oncologist · 2022 · 26 citations · Full text

, , +18

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Poornima Sharma, Yvette L. Kasamon, Xue Lin et al. · Clinical Cancer Research · 2023 · 21 citations · Full text

FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang et al. · Clinical Cancer Research · 2024 · 15 citations

, , +19

1–5 of 5